Covington, Fenwick Shape $3B Deal For California Drugmaker
Law360 (December 2, 2019, 8:06 PM EST) -- Japan's Astellas Pharma has agreed to pay roughly $3 billion for Audentes Therapeutics, a San Francisco-based drugmaker focused on treatments for rare neuromuscular conditions, the companies said Monday, in a deal guided by Covington & Burling and Fenwick & West.
The acquisition adds to Astellas Pharma Inc.'s portfolio a company in Audentes Therapeutics Inc. that develops drugs to treat a range of rare neuromuscular diseases, including myotubular myopathy, which is a life-threatening ailment that afflicts people with extreme muscle weakness, respiratory failure and early death, according to a statement. Audentes has a potential treatment for myotubular myopathy in development called AT132....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!